Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries. A promising strategy aimed at blocking the circulation of arboviruses is to release Aedes aegypti mosquitoes carrying the endosymbiotic bacterium Wolbachia. In 2019, the Wolbachia strategy was implemented in Nouméa as part of the World Mosquito Program. This intervention will modify the epidemiological profile of arboviruses in New Caledonia. Epidemiological surveillance of arboviruses requires molecular characterization of the virus contained in the serum obtained from the blood collected from patients. This molecular characterization by RNA isolation techniques, RT-qPCR monitoring and sequencing allows the construction of phylogenetic trees. In the context of the implementation of the World Mosquito Program in Nouméa, the investigators plan to follow the molecular evolution of arboviruses, over the period preceding the releases of mosquitoes carrying Wolbachia (from 1995 to 2019) then over a period of 5 years. following the releases. At the same time, the virus can be isolated by cell culture techniques and in vitro infections, allowing its study in vitro in cells or in vivo in mosquitoes. This study allows us to measure the impact of the Wolbachia strategy on the evolution of the virus's ability to replicate in cells in the presence of Wolbachia and to be transmitted by the mosquito.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Healthy Volunteers: f
View:

• Appearance of clinical signs suggestive of an infection with an arbovirus in the 7 days preceding the blood sample,

• Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another arbovirus.

• Patients or their representative (s) informed of the possible secondary use for research purposes of the samples initially taken for diagnostic purposes and their derivatives, and who have not since expressed their opposition to the secondary use of the samples diagnostics or their derivatives for research,

Locations
Other Locations
France
Centre Hospitalier Territorial
RECRUITING
Dumbéa Sur Mer
Contact Information
Primary
Myrielle Dupont-Rouzeyrol, PhD
mdupont@pasteur.nc
+687 27 75 30
Backup
Catherine Inizan, PhD
cinizan@pasteur.fr
+687 27 26 66
Time Frame
Start Date: 2020-07-17
Estimated Completion Date: 2025-07-17
Participants
Target number of participants: 600
Sponsors
Collaborators: Institut Pasteur de Nouvelle-Calédonie, Centre Hospitalier Territorial de Nouvelle-Calédonie
Leads: Institut Pasteur

This content was sourced from clinicaltrials.gov